Proton Therapy Failed to Extend Liver Cancer Survival
A study found that proton therapy did not improve survival rates compared to standard photon therapy for advanced liver cancer.
Updated on Sept. 29, 2026 in Cancer
Live Poll
Would you trust a new therapy if clinical trials show it performs similarly to traditional treatments?
The NRG-GI003 trial, which concluded enrollment in January 2026, revealed that proton radiation did not extend overall survival for patients with advanced liver cancer. The study compared the outcomes of 115 participants, aged 72 on average, across two different radiation delivery methods.
Why it matters
Understanding these results helps clarify the comparative effectiveness of advanced radiation technologies in managing liver malignancy. It informs how patients and their care teams weigh the potential for reduced side effects against overall survival outcomes.
In a randomized trial of 115 participants, proton therapy showed a median progression-free survival of 16.9 months compared to 13.7 months for photon therapy. While proton therapy reduced the radiation dose to healthy liver tissue, it did not demonstrate a survival benefit over 24 months.
The players
NRG-GI003
A clinical trial focused on comparing radiation therapies for liver cancer patients.
The details
Participants were randomly assigned to receive either proton or photon radiation therapy, with treatments delivered in five or 15 sessions. While proton therapy successfully delivered a lower median radiation dose to healthy liver tissue, this anatomical advantage did not translate into a mortality benefit. Researchers are now analyzing the trial data to identify potential subgroups that might show different responses to these radiation approaches.
Timeline
June 2017: Trial enrollment began.
January 2026: Trial enrollment ended.
Health Landscape
This study updates the medical community's understanding of proton therapy efficacy in the context of the NRG-GI003 trial. It shifts the focus from simply comparing dose delivery to assessing patient-centered survival outcomes.
If you are considering radiation options for liver cancer, discuss the trade-offs between different delivery methods with your oncology team. It is worth asking your doctor how specific clinical trial findings, such as these, apply to your individual diagnosis and tumor characteristics.
The takeaway
While proton therapy reduced radiation exposure to healthy liver tissue, it did not show superior survival benefits compared to photon radiation in this trial. Patients should maintain an open dialogue with their specialists about which treatment modality aligns best with their specific clinical needs.
Further reading
For more on the latest research and standard treatments for malignancies, visit our Cancer section.
Live Poll
Would you trust a new therapy if clinical trials show it performs similarly to traditional treatments?
